Experts Discuss Long-Term Effects and Monitoring in AD Therapy

Medical experts discuss the long-term consequences of extended use of topical corticosteroids or calcineurin inhibitors in atopic dermatitis (AD) patients and recommend appropriate monitoring strategies.

EP: 1.Tackling Key Concerns in Atopic Dermatitis + Biologic Use

EP: 2.Atopic Dermatitis: Topical Therapies and Unmet Needs in the Treatment Landscape

EP: 3.Going Beyond Topical Steroids and Calcineurin Inhibitors for AD Treatment

Now Viewing

EP: 4.Experts Discuss Long-Term Effects and Monitoring in AD Therapy

EP: 5.Balancing Safety and Efficacy: Optimizing Topical Treatment Options for AD

EP: 6.The Patient Journey: Effectively Managing AD Itch Early On

EP: 7.Streamlining Prior Authorization for Topical AD Therapies: Expert Strategies

EP: 8.Experts Share Final Insights to Optimize Atopic Dermatitis Patient Care

1. What are the implications of long-term use of topical corticosteroids or calcineurin inhibitors in AD patients, and how should patients be monitored for these?
   1. Also discuss how to address concerns related to systemic exposure/absorption of topical corticosteroids
2. What factors do you consider when deciding between topical and systemic therapies for patients needing treatment for AD?

Related Videos

Related Content

Advertisement

July 1st 2025

Challenges and Opportunities for AI in Melanoma Detection

AJMC Contributor

While artificial intelligence (AI) holds promise to improve the diagnosis of melanoma, researchers of a new review outlined challenges with these novel approaches.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

June 30th 2025

FDA Expands Access to Approved CAR T-Cell Therapies by Eliminating REMS

Brooke McCormick

The FDA has removed Risk Evaluation and Mitigation Strategies (REMS) for approved chimeric antigen receptor (CAR) T-cell therapies for hematologic malignancies, aiming to ease provider burden and expand patient access.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

June 26th 2025

Marstacimab Improved Key Bleeding Outcomes in Hemophilia A or B

Julia Bonavitacola

Primary and secondary end points were demonstrated in a phase 3 trial of subcutaneous marstacimab as treatment for patients with hemophilia A or B.

June 25th 2025

First-Line Rucaparib Maintenance Reduces Progression Risk Across Prognostic Subgroups in HRD– High-Grade Ovarian Cancer

Chris Ryan

Rucaparib maintenance improved progression-free survival (PFS) in homologous recombination deficiency (HRD)-negative advanced ovarian cancer, irrespective of baseline prognostic factors.

Related Content

Advertisement

July 1st 2025

Challenges and Opportunities for AI in Melanoma Detection

AJMC Contributor

While artificial intelligence (AI) holds promise to improve the diagnosis of melanoma, researchers of a new review outlined challenges with these novel approaches.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

June 30th 2025

FDA Expands Access to Approved CAR T-Cell Therapies by Eliminating REMS

Brooke McCormick

The FDA has removed Risk Evaluation and Mitigation Strategies (REMS) for approved chimeric antigen receptor (CAR) T-cell therapies for hematologic malignancies, aiming to ease provider burden and expand patient access.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

June 26th 2025

Marstacimab Improved Key Bleeding Outcomes in Hemophilia A or B

Julia Bonavitacola

Primary and secondary end points were demonstrated in a phase 3 trial of subcutaneous marstacimab as treatment for patients with hemophilia A or B.

June 25th 2025

First-Line Rucaparib Maintenance Reduces Progression Risk Across Prognostic Subgroups in HRD– High-Grade Ovarian Cancer

Chris Ryan

Rucaparib maintenance improved progression-free survival (PFS) in homologous recombination deficiency (HRD)-negative advanced ovarian cancer, irrespective of baseline prognostic factors.